Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents

✍ Scribed by Lawrence J. Wilson; Dennis C. Liotta

• Book ID: 102146386
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 78 KB
• Volume: 72
• Category: Article
• ISSN: 0272-4391
• DOI: 10.1002/ddr.20469

✦ Synopsis

Abstract

The chemokine CXCR4 receptor is a G‐protein‐coupled receptor that has multiple functions in normal physiologies involving the hematopoietic and immune systems. Although the CXCR4 receptor was initially discovered as one of the co‐receptors involved in human immune deficiency virus (HIV) cell entry, it has also been linked to many central immune system functions through the direct regulation of cell trafficking and adhesion, and is present in many cell types within the body. The receptor ligand combination of CXCL12 (SDF‐1) and CXCR4 underlies pathologies such as HIV infection, cancer metastasis and drug resistance, leukemia progression, rheumatoid arthritis, and lupus. This alternative and widespread functionality has allowed researchers to discover new potential uses for substances that are CXCR4 antagonists. This has resulted in approval of the first CXCR4 antagonist, plerixafor injection (AMD3100), for hematopoietic stem cell mobilization. Newer agents are under clinical evaluation for HIV, cancer, and stem cell mobilization. As these agents are further investigated, new uses and therapeutic interventions for CXCR4 antagonists will be discovered. Drug Dev Res 72:598–602, 2011. © 2011 Wiley Periodicals, Inc.